Differential Expression of Long Non-Coding RNA IGF2-AS in Tamoxifen-Resistant Breast Cancer Cells

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• Breast cancer, especially luminal subtype, often treated with endocrine therapy.
• Treatment resistance develops in 20-30% of patients, leading to aggressive disease.
• Long non-coding RNAs (lncRNAs) are increasingly recognized for their roles in cancer progression and therapeutic resistance.

Purpose of the Study:

• To investigate the role of the lncRNA insulin-like growth factor 2 antisense (IGF2-AS) in tamoxifen-resistant breast cancer.
• To assess IGF2-AS as a potential therapeutic target for overcoming tamoxifen resistance.

Main Methods:

• Quantitative PCR (qPCR) to measure IGF2-AS expression in tamoxifen-resistant (TAMR-V, TAMR-H) and control (MCF-7) cell lines.
• siRNA-mediated knockdown of IGF2-AS to assess its impact on cell proliferation, invasion, and migration.
• Next-generation sequencing (NGS) for differential gene expression analysis.
• Kaplan-Meier survival analysis to correlate IGF2-AS expression with patient prognosis.

Main Results:

• IGF2-AS expression was significantly upregulated in TAMR-V and TAMR-H cells compared to MCF-7 cells.
• IGF2-AS knockdown inhibited proliferation and invasion in TAMR-V cells, but not TAMR-H cells, indicating cell-specific roles.
• NGS revealed distinct gene expression profiles between TAMR-V and TAMR-H cells, highlighting varied resistance mechanisms.
• Elevated IGF2-AS expression correlated with poorer patient survival across multiple breast cancer subtypes.

Conclusions:

• IGF2-AS is upregulated in tamoxifen-resistant breast cancer and contributes to proliferation and invasion in a cell-specific manner.
• The differential expression of IGF2-AS in resistant cell lines underscores the complexity of resistance mechanisms.
• IGF2-AS presents a promising therapeutic target for overcoming tamoxifen resistance in breast cancer.